From The Editor
-
Turning “White Paper Ideas” Into Biomanufacturing Realities
10/19/2022
NIIMBL Director Kelvin H. Lee, Ph.D. illustrated the power of consortia and public/private partnerships in advancing next-generation approaches to ATMP manufacturing, and demonstrated how the Institute isn’t just talking — it’s building.
-
Biomanufacturing Capacity Crunch Part 2: Building Optionality
10/12/2022
In conference event programming, in the trade press, and in water cooler conversation we’re making too many generalizations—which in turn create misperceptions—about the so-called biopharmaceutical manufacturing “capacity” crunch.
-
Biomanufacturing Capacity Crunch: It’s The Supply Chain’s Fault
10/7/2022
What's behind the protracted biopharma manufacturing capacity crunch, when will it end, and what are manufacturers doing to keep supply on track? During Biotech Week in Boston ad BioProcess International, CDMOs and sponsors weighed in.
-
The “Liberation” Of Science Yields A New Class Of Biopharma Leadership
9/21/2022
Purespring Therapeutics’ Richard Francis is among the dozens of big pharma executives who have defected to biopharma startups on the science, tech, and finance tides. “When I saw some of the acquisitions we were doing, it occurred to me that there’s no correlation between the places from which good science is emerging and a big R&D budget," he says.
-
Biden’s Biologics Mandate And A Moonshot
9/19/2022
Thoughts on biotech executive orders, cancer cabinets, moon landings, and other important public/private partnership news you might have missed while the rest of the country was screaming at each other over inflation and social politics.
-
Nearing An IL-2, IL-15 Combination Inflection Point
9/11/2022
In a therapeutic space crowded with clinical activity, IL-2/IL-15 frontrunners are emerging, many of them in combination programs with big-time biologics. We caught up with one of those frontrunners, SOTIO CEO Radek Spisek, Ph.D., for perspective from the front of the pack.
-
Navigating A Clinical Hold
9/7/2022
FDA-ordered clinical holds are on the rise, and biologics IND are driving them. Immunome CEO Purnanand Sarma, Ph.D. shares his take on the role of the clinical hold, the biopharma’s appropriate response, and advice on obviating for the circumstance.
-
The Philogen Family Prepares For Market
9/6/2022
In 1996, Prof. Dario Neri and his brothers Duccio and Giovanni founded the biopharma Philogen. Today, three of the company’s 17 clinical-stage programs are in phase 3 trials, seven in phase 2. Prof. Neri offered insight into the company’s academically rooted, metered approach on episode 103 of the Business of Biotech podcast.
-
Are Fibroblasts Overlooked?
8/31/2022
Clinical-stage regenerative medicine company FibroBiologics is studying the use of fibroblasts in regenerative medicine for seemingly obvious applications like degenerative disc disease, but they’re also looking at the cells’ immune response implications in cancer and MS. Are readily-available fibroblasts undervalued in therapeutic research?
-
The Nuances Of Biopharma Portfolio Management
8/19/2022
Lara Sullivan, M.D. leans into the riches of her experience in big pharma R&D as she architects upstart Pyxis Oncology’s deep-and-wide portfolio. She shared much of her insight on the topic during a recent interview on the Business of Biotech podcast.